Dènyèman, pwojè rechèch klinik la nan selil souch 3D veso sangen bioprinting, ki te aplike pa West Lachin Lopital nan Sichuan University ak bay pwodwi ak sèvis teknik pa Sichuan Blu-ray Inno Biotechnology Co, Ltd. Nan 2022, rechèch klinik sou selil souch yo pral fèt nan West China Hospital nan Inivèsite Sichuan.
Founded in 2014, Blu-ray Inno is a high-tech enterprise focusing on stem cell tissue repair and regeneration. The company has independently developed the world's first stem cell Biosynsphere® (Biosynsphere®) technology platform with independent intellectual property rights, and based on this technology platform has developed a stem cell 3D bioprinted blood vessel (REVOVAS®), which has great clinical application value and is a stem cell A major breakthrough in tissue repair and regeneration.
Stem cell 3D bioprinted blood vessels REVOVAS®
REVOVAS® uses autologous adipose-derived mesenchymal stem cells as bio-ink raw materials, and prints biologically active blood vessels through a self-developed 3D bio-vascular printer, and implants receptors to replace diseased blood vessels. In the animal experiments of rhesus monkeys and Wuzhishan miniature pigs of this technology, it was observed that the implanted blood vessels achieved complete vascular tissue regeneration in a short period of time, with the function of normal blood vessels.
Kounye a, Blu-ray Inno te konplete famasi vaskilè ak famasi ak toksikoloji rechèch ki gen rapò sou selil tij 3D bioprinting, ki gen ladan pwosesis ak rechèch bon jan kalite nan kondisyon GMP, prèske 100 makak rhesus ak Wuzhishan tipòtrè eksperyans bèt anba kondisyon GLP, pami ki makak rhesus yo te obsève Sik ki pi long la te depase 1700 jou, ak tout endikatè sekirite yo te ranpli kondisyon yo. Pa gen stenoz nan veso sangen yo rejenere ki te fèt, epi moun k ap resevwa a pa bezwen pran dwòg antikoagulan pou yon tan long apre operasyon an.
Blu-ray Inno te konstwi tou yon sistèm jesyon kalite konplè pandan tout sik lavi pwodwi veso sangen 3D bioprinted selil souch yo, ki gen ladan prèske mil SOP tankou jesyon RD, jesyon pwodiksyon ak sistèm jesyon eksperyans bèt, ki soti nan matyè premyè. , pwodwi entèmedyè ak pwodwi final yo. Yo te etabli estanda konplè kontwòl kalite.
Stem cell 3D bioprinted blood vessels have superior performance in long-term patency rate and "autonomous" blood vessel formation. Once applied to the clinic, it will solve the problem of artificial blood vessel endothelialization that has plagued humans for half a century.
△Bio-brick preparation system (first from left, second from left) and real shot of bio-brick (first from right)
Anba background nan nan inovasyon nan mekanis rechèch klinik nasyonal selil souch la, teknoloji veso sangen 3D bioprinted selil souch la sipòte pa ajans regilasyon nan tout nivo, epi rechèch klinik yo pral fèt nan West China Hospital nan Inivèsite Sichuan nan 2022. menm tan an, Blu-ray Inno pral kontinye konplete materyèl done eksperimantal yo an akò ak egzijans aplikasyon esè klinik Lachin CDE ak US FDA, epi kontinye ankouraje esè klinik la ak maketing pwodwi nan selil souch la. 3D bioprinted pwojè veso sangen.
Pespektiv
Ak devlopman nan sosyete a ak ekonomi, mòd vi nou yo te chanje, espesyalman aje nan popilasyon an ak akselerasyon nan ibanizasyon. Vi ki malsen yo te vin de pli zan pli enpòtan. Maladi kadyovaskilè te vin nimewo en asasen sante pi lwen pase timè, ak pousantaj ensidans la toujou ap ogmante. .
According to the statistics of "China Cardiovascular Health and Disease Report 2020", cardiovascular disease currently accounts for the first cause of death among urban and rural residents in China, with 46.66 percent in rural areas and 43.81 percent in urban areas. The economic burden of cardiovascular disease on residents and society increasingly aggravated.
Rapò a fè remake ke prévalence maladi kadyovaskilè nan peyi mwen an se nan yon etap nan ogmantasyon kontinyèl, e li estime ke kantite moun ki soufri maladi kadyovaskilè se apeprè 330 milyon dola.
Atravè mond lan, plis pase 18 milyon moun mouri nan maladi kadyovaskilè ak serebwo vaskilè chak ane, pandan y ap gen apeprè 1.8 milya moun ki gen potansyèl maladi kadyovaskilè, ki vle di ke mwens pase 10 pousan nan pasyan atravè lemond yo te efektivman trete.
Rezon prensipal ki fè se tretman aktyèl maladi kadyovaskilè toujou limite a tretman sentòm tèminal yo.
Ki jan yo entèvni ak trete maladi nan premye etap la te vin tounen yon nouvo direksyon nan rechèch teknoloji medikal.
The multi-directional differentiation potential and self-replication ability of stem cells provide sufficient support for the development of "people-oriented" medical technology.
The REVOVAS® vascular technology was born under such a scientific background. It can repair vascular tissue in the early stage, eradicate the disease, improve the quality of life, and bring a new treatment concept and treatment plan to the majority of patients with cardiovascular disease.
Based on the Biosynsphere® technology platform, the Blu-ray Inno stem cell technology system also provides new solutions for the early treatment of similar chronic diseases.
